Q1 2023 EPS Estimates for Blueprint Medicines Co. Cut by Analyst (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities researchers at Wedbush lowered their Q1 2023 earnings per share estimates for Blueprint Medicines in a research report issued on Monday, April 24th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($2.43) per share for the quarter, down from their previous forecast […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Wellington ,New Zealand General ,New Zealand ,Blackrock ,United Kingdom General ,Stifel Nicolaus ,Christina Rossi ,Brian Druker ,Jeffreyw Albers ,Nicholasb Lydon ,Chris Varma ,Raymond James ,Blackrock Inc ,Blueprint Medicines Co ,Pricet Rowe Associates Inc ,Blueprint Medicines Corp ,Nasdaq ,Vanguard Group Inc ,Wellington Management Group ,Blueprint Medicines ,Get Rating ,Blueprint Medicine ,Director Jeffrey ,Management Group ,State Street Corp ,Street Corp ,Alexis Borisy ,Blueprint Medicines Daily ,Nasdaq Bpmc ,Bpmc ,Medical ,Earnings Estimates ,Wedbush ,